Abstract: AbstractThere is an expectation that to meet regulatory requirements, and avoid or minimize animal testing, integrated approaches to testing and assessment will be needed that rely on assays representing key events (KEs) in the skin sensitization adverse outcome pathway. Three non‐animal assays have been formally validated and regulatory adopted: the direct peptide reactivity assay (DPRA), the KeratinoSens™ assay and the human cell line activation test (h‐CLAT). There have been many efforts to develop integrated approaches to testing and ...
(read more)
Topics: 
Computational biology
Toxicology